Farid Jamshidian

889 total citations
27 papers, 397 citations indexed

About

Farid Jamshidian is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Farid Jamshidian has authored 27 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cancer Research, 11 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Farid Jamshidian's work include Breast Cancer Treatment Studies (15 papers), Cancer Genomics and Diagnostics (6 papers) and Advanced Breast Cancer Therapies (5 papers). Farid Jamshidian is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), Cancer Genomics and Diagnostics (6 papers) and Advanced Breast Cancer Therapies (5 papers). Farid Jamshidian collaborates with scholars based in United States, France and United Kingdom. Farid Jamshidian's co-authors include Steven M. Butler, Steven Shak, Frederick L. Baehner, Norman Wolmark, Eleftherios P. Mamounas, Gong Tang, Soonmyung Paik, Amy P. Sing, Diana B. Cherbavaz and Barry C. Lembersky and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Farid Jamshidian

27 papers receiving 391 citations

Peers

Farid Jamshidian

ONCOL

PFM

GENET

PRM

Nicky Liebermann Israel

R Margolese United States

M.J. Mitchell United Kingdom

Stephen DeSantis United States

Kate Whelan United States

Olivier Brouckaert Belgium

Regina Große Germany

Ilse Jannink Netherlands

Mária Gere Sweden

Domen Ribnikar Canada

Nicky Liebermann Israel

Farid Jamshidian

228 ×0.8

159 ×0.9

ONCOL

80 ×0.7

PFM

96 ×1.1

GENET

50 ×0.6

PRM

Citations per year, relative to Farid Jamshidian Farid Jamshidian (= 1×) peers Nicky Liebermann

Countries citing papers authored by Farid Jamshidian

Since Specialization

Citations

This map shows the geographic impact of Farid Jamshidian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farid Jamshidian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farid Jamshidian more than expected).

Fields of papers citing papers by Farid Jamshidian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farid Jamshidian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farid Jamshidian. The network helps show where Farid Jamshidian may publish in the future.

Co-authorship network of co-authors of Farid Jamshidian

This figure shows the co-authorship network connecting the top 25 collaborators of Farid Jamshidian. A scholar is included among the top collaborators of Farid Jamshidian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farid Jamshidian. Farid Jamshidian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Álvarez, Elena, Lucy Campbell, Willard Tinago, et al.. (2022). The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study. Antiviral Therapy. 27(4). 201820658–201820658. 2 indexed citations

Mamounas, Eleftherios P., Qing Liu, Soonmyung Paik, et al.. (2017). 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. JNCI Journal of the National Cancer Institute. 109(4). djw259–djw259. 103 indexed citations

Mamounas, Eleftherios P., Gong Tang, Soonmyung Paik, et al.. (2017). 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Research and Treatment. 168(1). 69–77. 33 indexed citations

Perez, Edith A., Frederick L. Baehner, Steven M. Butler, et al.. (2015). The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. Breast Cancer Research. 17(1). 133–133. 17 indexed citations

Pivot, Xavier, Laura Mansi, L. Chaigneau, et al.. (2015). In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?. The Oncologist. 20(4). 344–350. 19 indexed citations

Mamounas, E., Norman Wolmark, Gong Tang, et al.. (2015). P264 Predicting late distant recurrence risk in ER+ breast cancer after five years of tamoxifen. The Breast. 24. S117–S117. 1 indexed citations

Rakovitch, Eileen, Sharon Nofech‐Mozes, Wedad Hanna, et al.. (2015). Correlation between the DCIS Score and traditional clinicopathologic features in the prospectively-designed Ontario population-based validation study.. Journal of Clinical Oncology. 33(15_suppl). 581–581. 1 indexed citations

Powell, Mark, Farid Jamshidian, Karla Kerlikowske, et al.. (2014). First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. Cancer Causes & Control. 25(7). 859–868. 20 indexed citations

Wolmark, Norman, Eleftherios P. Mamounas, Frederick L. Baehner, et al.. (2014). Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen.. Journal of Clinical Oncology. 32(15_suppl). 11024–11024. 6 indexed citations

10.

Powell, Mark, et al.. (2013). Assessing Breast Cancer Risk Models in Marin County, a Population With High Rates of Delayed Childbirth. Clinical Breast Cancer. 14(3). 212–220.e1. 18 indexed citations

11.

Singh, Bhawana, et al.. (2013). Abstract P3-05-08: Discordance in hormone receptor (HR) assessment by IHC and RT-PCR in an estrogen receptor (ER) low-positive group (1-10% positive cells): Does accurate assessment of HR status require dual testing?. Cancer Research. 73(24_Supplement). P3–5. 1 indexed citations

12.

Powell, Mark, et al.. (2013). Abstract P3-07-03: Insulin-like growth factor-1 receptor variant associated with decreased breast cancer risk in women with pregnancy-induced hypertension. Cancer Research. 73(24_Supplement). P3–7. 3 indexed citations

13.

Vacirca, Jeffrey, Michaela L. Tsai, Adam Brufsky, et al.. (2013). Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC).. Journal of Clinical Oncology. 31(15_suppl). 565–565. 2 indexed citations

14.

Hubbard, Alan, Farid Jamshidian, & Nicholas P. Jewell. (2012). Adjusting for Perception and Unmasking Effects in Longitudinal Clinical Trials. The International Journal of Biostatistics. 8(2). 1–20. 9 indexed citations

15.

Mamounas, Eleftherios P., Gong Tang, Soonmyung Paik, et al.. (2012). Abstract P6-07-01: Prognostic impact of the 21-gene Recurrence Score (RS) on loco-regional recurrence (LRR) of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28. Cancer Research. 72(24_Supplement). P6–7. 3 indexed citations

16.

Baehner, Frederick L., Steven M. Butler, Carl Yoshizawa, et al.. (2012). The development of the DCIS score: Scaling and normalization in the Marin General Hospital cohort.. Journal of Clinical Oncology. 30(27_suppl). 190–190. 1 indexed citations

17.

Poulet, B., et al.. (2012). Abstract P6-07-03: Risk classification of Early Stage Breast Cancer as Assessed by MammaPrint and Oncotype DX Genomic Assays. Cancer Research. 72(24_Supplement). P6–7. 9 indexed citations

18.

Mamounas, Eleftherios P., Gong Tang, Soonmyung Paik, et al.. (2012). Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28.. Journal of Clinical Oncology. 30(27_suppl). 1–1. 22 indexed citations

19.

Jamshidian, Farid, Alan Hubbard, & Nicholas P. Jewell. (2011). Accounting for perception, placebo and unmasking effects in estimating treatment effects in randomised clinical trials. Statistical Methods in Medical Research. 23(3). 293–307. 13 indexed citations

20.

Jamshidian, Mortaza, et al.. (2005). SimReg: A Software Includinge Some New Developments in Multiple Comparison and Simultaneous Confidence Bands for Linear Regression Models. Journal of Statistical Software. 12(2). 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact